Nine cases of symptomatic bradycardia are presented in which treatment with intravenous glucagon was administered when atropine failed to improve the patient's condition significantly. Although the cause often was not obvious at presentation, all nine subjects took oral medications that could have contributed to the development of symptomatic bradycardia. Eight of nine patients demonstrated clinical improvement 5 to 10 min after glucagon administration, which was consistent with its peak clinical action. Beta-blockers, calcium channel blockers, and digoxin were ultimately thought to have contributed to the majority of these presentations. This report suggests that glucagon may have a role in the treatment of symptomatic bradycardia, particularly in the presence of beta-adrenergic blockade and perhaps calcium channel blockade. Furthermore, the results in these cases suggest that future clinical trials should not be limited to drug-induced symptomatic bradycardia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1378/chest.114.1.323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Growth Differentiation Factor 15 as a Marker for Chronic Ventricular Pacing.
J Clin Med
December 2024
Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria.
Right ventricular pacing is an effective and safe treatment option for patients experiencing symptomatic bradycardia. However, some individuals may develop left ventricular dysfunction as a consequence. Growth differentiation factor 15 (GDF-15), which is not present in a healthy adult heart, is upregulated in cardiomyocytes in response to various stress stimuli.
View Article and Find Full Text PDFBAY 2413555 is a novel selective and reversible positive allosteric modulator of the type 2 muscarinic acetylcholine (M2) receptor, aimed at enhancing parasympathetic signaling and restoring cardiac autonomic balance for the treatment of heart failure (HF). This study tested the safety, tolerability and pharmacokinetics of this novel therapeutic option. REMOTE-HF was a multicenter, double-blind, randomized, placebo-controlled, phase Ib dose-titration study with two active arms.
View Article and Find Full Text PDFPersonalized Accelerated Physiologic Dual Rate Pacing for Cardiac Amyloidosis.
JACC Case Rep
November 2024
Department of Medicine, Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota, USA.
A 78-year-old man with cardiac amyloidosis developed sinus bradycardia with symptomatic hypotension. Three months after receiving an advanced biventricular pacemaker system with continuous accelerated rate pacing (daytime: 70 beats/min; nighttime: 90 beats/min), his health status and symptoms were markedly improved.
View Article and Find Full Text PDFLeft internal jugular vein approach to right atrial appendage base implantation of the Aveir AR leadless pacemaker.
Indian Pacing Electrophysiol J
December 2024
Division of Pediatric Cardiology and Adult Congenital Cardiology, UC Davis Medical Center, Sacramento, USA. Electronic address:
Introduction: There is no prior report of an Aveir leadless pacemaker implantation into the atrial appendage via the internal jugular vein.
Case: A 44-year-old female patient with history of multiple ablations for sinus node dysfunction presented with symptomatic bradycardia. The patient had femoral veins <9mm, chronic pain at the femoral vein insertion sites, as well as a recent car accident with persistent leg pain due to femoral fractures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!